300158 振东制药
已收盘 10-09 15:00:00
资讯
新帖
简况
股市必读：振东制药（300158）10月8日董秘有最新回复
证券之星 · 10-09 03:15
股市必读：振东制药（300158）10月8日董秘有最新回复
振东制药：复方苦参注射液为公司抗肿瘤中药注射剂，用于癌肿疼痛、出血
证券之星 · 10-08 20:48
振东制药：复方苦参注射液为公司抗肿瘤中药注射剂，用于癌肿疼痛、出血
振东制药：现有复方苦参注射液、西黄丸、独一味颗粒、大山楂丸等成熟中药产品
证券之星 · 09-17
振东制药：现有复方苦参注射液、西黄丸、独一味颗粒、大山楂丸等成熟中药产品
振东制药：复方匹可硫酸钠颗粒目前购买渠道主要以院边药店为主
证券之星 · 09-04
振东制药：复方匹可硫酸钠颗粒目前购买渠道主要以院边药店为主
振东制药：磷酸芦可替尼乳膏项目相关研发工作正在正常推进中
证券之星 · 09-02
振东制药：磷酸芦可替尼乳膏项目相关研发工作正在正常推进中
股市必读：振东制药（300158）8月27日董秘有最新回复
证券之星 · 08-28
股市必读：振东制药（300158）8月27日董秘有最新回复
振东制药：格氏乳杆菌二联活菌胶囊目前药品上市申请审评工作正常推进中
证券之星 · 08-27
振东制药：格氏乳杆菌二联活菌胶囊目前药品上市申请审评工作正常推进中
振东制药2026年中报：战略调整营收承压 研发逆势加码
中国财富通 · 08-26
振东制药2026年中报：战略调整营收承压 研发逆势加码
振东制药上半年同比由盈转亏 前海人寿保险为前十股东
中金财经 · 08-26
振东制药上半年同比由盈转亏 前海人寿保险为前十股东
股市必读：振东制药新发布《2026年半年度报告摘要》
证券之星 · 08-26
股市必读：振东制药新发布《2026年半年度报告摘要》
图解振东制药中报：第二季度单季净利润同比下降1453.38%
证券之星 · 08-26
图解振东制药中报：第二季度单季净利润同比下降1453.38%
振东制药（300158）披露向银行申请授信额度并接受关联方担保暨关联交易公告，8月6日股价下跌0.4%
证券之星 · 08-06
振东制药（300158）披露向银行申请授信额度并接受关联方担保暨关联交易公告，8月6日股价下跌0.4%
振东制药获得发明专利授权：“壬二酸微乳及其制备方法和应用”
证券之星 · 08-01
振东制药获得发明专利授权：“壬二酸微乳及其制备方法和应用”
振东制药：治疗细菌性阴道炎的格氏乳杆菌二联活菌胶囊NDA已获CDE受理
证券之星 · 07-30
振东制药：治疗细菌性阴道炎的格氏乳杆菌二联活菌胶囊NDA已获CDE受理
振东制药：格氏乳杆菌二联活菌阴道胶囊处于生产许可审批阶段
证券之星 · 07-23
振东制药：格氏乳杆菌二联活菌阴道胶囊处于生产许可审批阶段
股市必读：振东制药（300158）7月21日董秘有最新回复
证券之星 · 07-22
股市必读：振东制药（300158）7月21日董秘有最新回复
振东制药：公司参股的龙创基药业已完成格氏乳杆菌二联活菌胶囊生产线建设并通过GMP符合性检查
证券之星 · 07-03
振东制药：公司参股的龙创基药业已完成格氏乳杆菌二联活菌胶囊生产线建设并通过GMP符合性检查
振东制药（300158）披露聘任董事会秘书公告，7月1日股价上涨4.99%
证券之星 · 07-01
振东制药（300158）披露聘任董事会秘书公告，7月1日股价上涨4.99%
股市必读：振东制药（300158）6月1日披露最新机构调研信息
证券之星 · 06-02
股市必读：振东制药（300158）6月1日披露最新机构调研信息
振东制药（300158）披露股东股份质押公告，5月28日股价上涨0.81%
证券之星 · 05-28
振东制药（300158）披露股东股份质押公告，5月28日股价上涨0.81%
加载更多
公司概况
公司名称：
山西振东制药股份有限公司
所属行业：
医药制造业
上市日期：
2011-01-07
主营业务：
山西振东制药股份有限公司的主营业务是肿瘤、皮科、消化、泌尿、心脑等仿制药、创新药的研发、生产、销售，以及种子种苗抚育、种植、加工、仓储、饮片于一体的中药材全产业链。公司的主要产品是中成药、化药。
发行价格：
38.80
{"stockData":{"symbol":"300158","market":"SZ","secType":"STK","nameCN":"振东制药","latestPrice":5.31,"timestamp":1791529434000,"preClose":5.15,"halted":0,"volume":18811521,"delay":0,"changeRate":0.0311,"floatShares":992000000,"shares":992000000,"eps":-0.4049,"marketStatus":"已收盘","change":0.16,"latestTime":"10-09 15:00:00","open":5.15,"high":5.34,"low":5.06,"amount":97976100,"amplitude":0.0544,"askPrice":5.31,"askSize":3523,"bidPrice":5.3,"bidSize":1944,"shortable":0,"etf":0,"ttmEps":-0.4049,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791768600000},"marketStatusCode":5,"adr":0,"adjPreClose":5.15,"symbolType":"stock","openAndCloseTimeList":[[1791509400000,1791516600000],[1791522000000,1791529200000]],"highLimit":5.67,"lowLimit":4.64,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":992303056,"isCdr":false,"pbRate":1.57,"roa":"--","roe":"--","epsLYR":-0.2998,"committee":-0.492626,"marketValue":5269000000,"turnoverRate":0.019,"status":0,"floatMarketCap":5266000000},"requestUrl":"/m/hq/s/300158","defaultTab":"news","newsList":[{"id":"2674002060","title":"股市必读：振东制药（300158）10月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2674002060","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674002060?lang=zh_cn&edition=full","pubTime":"2026-10-09 03:15","pubTimestamp":1791486912,"startTime":"0","endTime":"0","summary":"截至2026年10月8日收盘，振东制药报收于5.15元，下跌1.15%，换手率1.2%，成交量11.86万手，成交额6143.89万元。董秘最新回复投资者： 公司复方苦参注射液对克罗恩病有没有抑制作用？复方苦参注射液为公司抗肿瘤中药注射剂，用于癌肿疼痛、出血。当日关注点交易信息汇总：10月8日主力资金净流入118.81万元，占总成交额1.93%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900002828.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0060","300158","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673772080","title":"振东制药：复方苦参注射液为公司抗肿瘤中药注射剂，用于癌肿疼痛、出血","url":"https://stock-news.laohu8.com/highlight/detail?id=2673772080","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673772080?lang=zh_cn&edition=full","pubTime":"2026-10-08 20:48","pubTimestamp":1791463690,"startTime":"0","endTime":"0","summary":"证券之星消息，振东制药10月08日在投资者关系平台上答复投资者关心的问题。非常感谢您的提问以及对公司中药研发方向提出的宝贵建议。复方苦参注射液为公司抗肿瘤中药注射剂，用于癌肿疼痛、出血。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800031933.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300158","BK0186","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668967562","title":"振东制药：现有复方苦参注射液、西黄丸、独一味颗粒、大山楂丸等成熟中药产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2668967562","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668967562?lang=zh_cn&edition=full","pubTime":"2026-09-17 20:51","pubTimestamp":1789649493,"startTime":"0","endTime":"0","summary":"证券之星消息，振东制药09月17日在投资者关系平台上答复投资者关心的问题。公司依托中药材资源优势，持续布局中药业务，现有复方苦参注射液、西黄丸、独一味颗粒、大山楂丸等成熟中药产品。关于在研新药核准进展，如后续达到信息披露标准，公司将严格按照监管要求及时对外披露。药品研发及注册审批周期长、环节多，最终能否顺利获批、获批时间及上市后的市场销售情况均存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091700034408.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300158","BK0239","BK0186","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664733426","title":"振东制药：复方匹可硫酸钠颗粒目前购买渠道主要以院边药店为主","url":"https://stock-news.laohu8.com/highlight/detail?id=2664733426","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664733426?lang=zh_cn&edition=full","pubTime":"2026-09-04 20:51","pubTimestamp":1788526274,"startTime":"0","endTime":"0","summary":"证券之星消息，振东制药(300158)09月03日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好：公司去年代理的辉凌制药原研的肠道药物复方匹可硫酸钠颗粒）这药评论说味道好，对肾影响小）！今天去三甲医院做肠胃镜，医生说没这个药（福建），开出药方还是那种很难喝的药！请问你们药品布局这么慢吗？还是有地域限制营销？谢谢！振东制药回复：尊敬的投资者您好！复方匹可硫酸钠颗粒目前购买渠道主要以院边药店为主，也可以通过线上正规渠道购买。公司会持续加快市场布局和院端准入工作。感谢您的支持与关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400039222.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","300158","BK0186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664681466","title":"振东制药：磷酸芦可替尼乳膏项目相关研发工作正在正常推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2664681466","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664681466?lang=zh_cn&edition=full","pubTime":"2026-09-02 20:51","pubTimestamp":1788353501,"startTime":"0","endTime":"0","summary":"证券之星消息，振东制药09月01日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好：2025年年报披露公司正在研发治疗白癜风的靶向药：磷酸芦可替尼乳膏！公司磷酸芦可替尼乳膏项目相关研发工作正在正常推进中。后续如有达到信息披露标准的重大进展，公司将严格按照监管规定及时履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200040565.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300158","BK0186","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662203126","title":"股市必读：振东制药（300158）8月27日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2662203126","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662203126?lang=zh_cn&edition=full","pubTime":"2026-08-28 07:34","pubTimestamp":1787873656,"startTime":"0","endTime":"0","summary":"截至2026年8月27日收盘，振东制药报收于5.25元，上涨0.19%，换手率1.61%，成交量15.96万手，成交额8392.42万元。董秘最新回复投资者： 董秘你好：今天从CDE网站了解到，公司重要生物制品：乳酸菌胶囊今天已经出列，祝贺！后续如有达到信息披露标准的重大进展，公司将严格按照监管规定及时履行信息披露义务。当日关注点交易信息汇总：8月27日主力资金净流入133.06万元，占总成交额1.59%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800013878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","300158","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662003617","title":"振东制药：格氏乳杆菌二联活菌胶囊目前药品上市申请审评工作正常推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2662003617","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662003617?lang=zh_cn&edition=full","pubTime":"2026-08-27 20:48","pubTimestamp":1787834906,"startTime":"0","endTime":"0","summary":"证券之星消息，振东制药08月27日在投资者关系平台上答复投资者关心的问题。格氏乳杆菌二联活菌胶囊目前药品上市申请审评工作正常推进中。后续如有达到信息披露标准的重大进展，公司将严格按照监管规定及时履行信息披露义务。药品研发及注册审批周期长、环节多，最终能否顺利获批、获批时间及上市后的市场销售情况均存在不确定性，敬请广大投资者理性投资，注意投资风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700051156.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","BK0186","300158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662792791","title":"振东制药2026年中报：战略调整营收承压 研发逆势加码","url":"https://stock-news.laohu8.com/highlight/detail?id=2662792791","media":"中国财富通","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662792791?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:54","pubTimestamp":1787738073,"startTime":"0","endTime":"0","summary":"振东制药于8月25日晚间披露2026年半年度报告。报告期内，中药毛利率49.87%，化药毛利率57.14%，销售费用同比下降19.67%，显示降本增效措施具有一定成效。报告期内，公司研发投入合计1.13亿元，较上年同期增长23.43%。其中，男用米诺地尔泡沫剂已于2026年4月获国家药监局药品审评中心受理上市许可申请；非那雄胺片、二硫化硒洗剂等多款皮科用药处于申报上市阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=3x4TQQfRN7c%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662793363","title":"振东制药上半年同比由盈转亏 前海人寿保险为前十股东","url":"https://stock-news.laohu8.com/highlight/detail?id=2662793363","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662793363?lang=zh_cn&edition=full","pubTime":"2026-08-26 15:14","pubTimestamp":1787728442,"startTime":"0","endTime":"0","summary":"中国经济网北京8月26日讯 振东制药(300158.SZ)昨晚发布2026年半年度报告。\r\n\r\n 报告期内，公司营业收入为10.97亿元，同比减少24.74%；归属于上市公司股东的净利润-9272.55万元，上年同期为793.13万元，同比由盈转亏；归属于上市公司股东的扣除非经常性损益的净利润-1.07亿元，上年同期为-817.64万元；经营活动产生的现金流量净额-3.48亿元。\r\n\r\n \r\n\r\n 截止2026年6月30日，前海人寿保险股份有限公司-自有资金为公司第三大股东，持股21699940股，持股比例2.19%。\r\n\r\n \r\n\r\n (责任编辑：孙辰炜)","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202608/26/20260826827238.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202608/26/20260826827238.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260826/32347996.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0186","BK0239","300158","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662754601","title":"股市必读：振东制药新发布《2026年半年度报告摘要》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662754601","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662754601?lang=zh_cn&edition=full","pubTime":"2026-08-26 03:58","pubTimestamp":1787687922,"startTime":"0","endTime":"0","summary":"截至2026年8月25日收盘，振东制药报收于5.31元，上涨4.12%，换手率2.49%，成交量24.67万手，成交额1.29亿元。当日关注点交易信息汇总：8月25日主力资金净流出809.14万元，占总成交额6.27%； 公司公告汇总：振东制药2026年半年度报告披露，营业收入同比下降24.74%，归母净利润为-9272.55万元，同比下降1269.11%； 交易信息汇总资金流向8月25日主力资金净流出809.14万元，占总成交额6.27%；游资资金净流出365.35万元，占总成交额2.83%；散户资金净流入1174.49万元，占总成交额9.1%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600007630.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300158","BK0060","BK0186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662751241","title":"图解振东制药中报：第二季度单季净利润同比下降1453.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662751241","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662751241?lang=zh_cn&edition=full","pubTime":"2026-08-26 03:10","pubTimestamp":1787685024,"startTime":"0","endTime":"0","summary":"证券之星消息，振东制药2026年中报显示，上半年度公司主营收入10.97亿元，同比下降24.74%；归母净利润-9272.55万元，同比下降1269.11%；扣非净利润-1.07亿元，同比下降1214.56%；其中2026年第二季度，公司单季度主营收入4.47亿元，同比下降36.31%；单季度归母净利润-9167.96万元，同比下降1453.38%；单季度扣非净利润-9637.1万元，同比下降1038.33%；负债率24.73%，投资收益33.1万元，财务费用333.84万元，毛利率53.1%。财报数据概要请见下图:本文数据来源于振东制药2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600005462.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657630456","title":"振东制药（300158）披露向银行申请授信额度并接受关联方担保暨关联交易公告，8月6日股价下跌0.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657630456","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657630456?lang=zh_cn&edition=full","pubTime":"2026-08-06 22:23","pubTimestamp":1786026198,"startTime":"0","endTime":"0","summary":"截至2026年8月6日收盘，振东制药报收于5.01元，较前一交易日下跌0.4%，最新总市值为49.71亿元。近日，振东制药披露《关于公司向银行申请授信额度并接受关联方担保暨关联交易的公告》。上述担保事项构成关联交易，但属于公司单方面获得利益的交易，已由第六届董事会第十五次会议审议通过，无需提交股东大会审议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600039924.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","161121","BK0186","300158","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656399846","title":"振东制药获得发明专利授权：“壬二酸微乳及其制备方法和应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2656399846","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656399846?lang=zh_cn&edition=full","pubTime":"2026-08-01 03:41","pubTimestamp":1785526885,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示振东制药新获得一项发明专利授权，专利名为“壬二酸微乳及其制备方法和应用”，专利申请号为CN202310253512.8，授权日为2026年7月31日。本发明将壬二酸制成微乳，在保证其使用效果前提下，减少壬二酸的刺激性，提高透皮吸收率，同时还具有安全性高、粒径小、易于保存、使用方便、溶解性好、配伍性佳、制备简单、成本低、利于扩大生产等优点。今年以来振东制药新获得专利授权8个，较去年同期增加了166.67%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080100004246.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0060","300158","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655152870","title":"振东制药：治疗细菌性阴道炎的格氏乳杆菌二联活菌胶囊NDA已获CDE受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2655152870","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655152870?lang=zh_cn&edition=full","pubTime":"2026-07-30 20:52","pubTimestamp":1785415924,"startTime":"0","endTime":"0","summary":"证券之星消息，振东制药(300158)07月29日在投资者关系平台上答复投资者关心的问题。投资者提问：公司在研的创新药有哪些？主要用于治疗哪些病症？目前处于什么阶段？振东制药回复：尊敬的投资者您好！目前公司引进的创新药为治疗细菌性阴道炎的格氏乳杆菌二联活菌胶囊，该产品上市许可申请（NDA）已于2025年12月获国家药监局药品审评中心（CDE）正式受理，目前正处于正常审批流程中。药品研发周期长，药品上市存在不确定性，后续有涉及披露事项公司会及时公告。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000037388.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","300158","BK0186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653728241","title":"振东制药：格氏乳杆菌二联活菌阴道胶囊处于生产许可审批阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2653728241","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653728241?lang=zh_cn&edition=full","pubTime":"2026-07-23 20:57","pubTimestamp":1784811461,"startTime":"0","endTime":"0","summary":"证券之星消息，振东制药07月22日在投资者关系平台上答复投资者关心的问题。二级市场股价受多重因素影响。经营层面，公司持续深耕主业、稳步推进创新布局，引进品种 “格氏乳杆菌二联活菌阴道胶囊” 目前处于国家药监局生产许可审批阶段。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300045764.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0060","300158","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653158207","title":"股市必读：振东制药（300158）7月21日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2653158207","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653158207?lang=zh_cn&edition=full","pubTime":"2026-07-22 02:39","pubTimestamp":1784659142,"startTime":"0","endTime":"0","summary":"截至2026年7月21日收盘，振东制药报收于4.83元，下跌1.83%，换手率1.96%，成交量19.4万手，成交额9224.24万元。公司相关药物的研发进展情况请关注公司已发布的公告。目前，公司不存在应披露而未披露的重大事项。后续若有相关重大进展，公司将严格按照相关法律法规及信息披露规则，及时履行信息披露义务。当日关注点交易信息汇总：7月21日振东制药主力资金净流出143.86万元，游资资金净流入772.05万元，散户资金净流出628.2万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200003199.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300158","BK0186","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648667126","title":"振东制药：公司参股的龙创基药业已完成格氏乳杆菌二联活菌胶囊生产线建设并通过GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2648667126","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648667126?lang=zh_cn&edition=full","pubTime":"2026-07-03 20:51","pubTimestamp":1783083099,"startTime":"0","endTime":"0","summary":"证券之星消息，振东制药(300158)07月02日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，请问振东制药创新药二联活菌胶囊生产线是否已建设完成？中药创新药星篓承气颗粒临床进展是否一切顺利？振东制药回复：尊敬的投资者您好！ 为加快商业化进程，公司参股的龙创基药业已完成格氏乳杆菌二联活菌胶囊生产线建设并通过GMP符合性检查。药品研发周期长，药品上市存在不确定性，后续有涉及披露事项公司会及时公告。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300043005.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0186","BK0060","300158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648511129","title":"振东制药（300158）披露聘任董事会秘书公告，7月1日股价上涨4.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648511129","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648511129?lang=zh_cn&edition=full","pubTime":"2026-07-01 17:48","pubTimestamp":1782899310,"startTime":"0","endTime":"0","summary":"截至2026年7月1日收盘，振东制药报收于4.84元，较前一交易日上涨4.99%，最新总市值为48.03亿元。近日，振东制药发布《关于聘任董事会秘书的公告》。公告显示，公司于2026年6月30日召开第六届董事会第十四次会议，审议通过聘任郭海波先生为公司董事会秘书的议案。任期自董事会审议通过之日起至第六届董事会届满为止。郭海波先生未持有公司股份，与控股股东、实际控制人及其他主要股东无关联关系，未受过相关监管部门处罚。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100034597.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0239","BK0060","300158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640440966","title":"股市必读：振东制药（300158）6月1日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2640440966","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640440966?lang=zh_cn&edition=full","pubTime":"2026-06-02 01:49","pubTimestamp":1780336150,"startTime":"0","endTime":"0","summary":"截至2026年6月1日收盘，振东制药报收于5.12元，上涨1.79%，换手率1.05%，成交量10.38万手，成交额5285.52万元。来自机构调研要点：阴道用乳杆菌二联活菌胶囊已于2025年12月获CDE受理，处于正常审批流程中。复方苦参注射液截至2025年连续多年位居用药人次首位，品牌势能稳定释放，年销售额保持稳定，为公司中药板块核心盈利品种。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200001470.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300158","BK0239","BK0186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638616466","title":"振东制药（300158）披露股东股份质押公告，5月28日股价上涨0.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638616466","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638616466?lang=zh_cn&edition=full","pubTime":"2026-05-28 17:34","pubTimestamp":1779960873,"startTime":"0","endTime":"0","summary":"截至2026年5月28日收盘，振东制药报收于4.99元，较前一交易日上涨0.81%，最新总市值为49.52亿元。近日，振东制药发布《关于股东股份质押的公告》。公告显示，公司控股股东山西振东健康产业集团有限公司将其持有的11,200,000股公司股份质押给中国银行股份有限公司长治市分行，占其所持股份比例3.71%，占公司总股本比例1.13%，质押用途为自身生产经营。本次质押后，振东集团累计质押股份143,800,000股，占其所持股份比例47.58%，占公司总股本比例14.49%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052800031612.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","300158","BK0186"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791610672867,"stockEarnings":[{"period":"1week","weight":0.0192},{"period":"1month","weight":-0.0148},{"period":"3month","weight":0.0837},{"period":"6month","weight":-0.1366},{"period":"1year","weight":-0.1967},{"period":"ytd","weight":-0.0861}],"compareEarnings":[{"period":"1week","weight":-0.0074},{"period":"1month","weight":-0.0349},{"period":"3month","weight":-0.0456},{"period":"6month","weight":-0.0433},{"period":"1year","weight":-0.0305},{"period":"ytd","weight":-0.0391}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"山西振东制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"41868人(较上一季度减少18.69%)","perCapita":"23685股","listingDate":"2011-01-07","address":"山西省长治市上党区光明南路振东科技园","registeredCapital":"99230万元","survey":" 山西振东制药股份有限公司的主营业务是肿瘤、皮科、消化、泌尿、心脑等仿制药、创新药的研发、生产、销售，以及种子种苗抚育、种植、加工、仓储、饮片于一体的中药材全产业链。公司的主要产品是中成药、化药。","listedPrice":38.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"振东制药(300158)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供振东制药(300158)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"振东制药,300158,振东制药股票,振东制药股票老虎,振东制药股票老虎国际,振东制药行情,振东制药股票行情,振东制药股价,振东制药股市,振东制药股票价格,振东制药股票交易,振东制药股票购买,振东制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"振东制药(300158)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供振东制药(300158)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}